Advanced search×

Rational design of dualsteric GPCR ligands: quests and promise.

Br J Pharmacol 159(5):997-1008 (2010) PMID 20136835

Dualsteric ligands represent a novel mode of targeting G protein-coupled receptors (GPCRs). These compounds attach simultaneously to both, the orthosteric transmitter binding site and an additional allosteric binding area of a receptor protein. This approach allows the exploitation of favourable characteristics of the orthosteric and the allosteric site by a single ligand molecule. The orthosteric interaction provides high affinity binding and activation of receptors. The allosteric interaction yields receptor subtype-selectivity and, in addition, may modulate both, efficacy and intracellular signalling pathway activation. Insight into the spatial arrangement of the orthosteric and the allosteric site is far advanced in the muscarinic acetylcholine receptor, and the design of dualsteric muscarinic agonists has now been accomplished. Using the muscarinic receptor as a paradigm, this review summarizes the way from suggestive evidence for an orthosteric/allosteric overlap binding to the rational design and experimental validation of dualsteric ligands. As allosteric interactions are increasingly described for GPCRs and as insight into the spatial geometry of ligand/GPCR-complexes is growing impressively, the rational design of dualsteric drugs is a promising new approach to achieve fine-tuned GPCR-modulation.

DOI: 10.1111/j.1476-5381.2009.00601.x
Version: za2963e q8za6 q8zb3 q8zcc q8zdb q8zef q8zfc q8zg8

Similar articles you may find interesting…

  1. Novel CRTH2 antagonists: a review of patents from 2006 to 2009.

    Expert Opin Ther Pat 20(11):1505-30 (2010) PMID 20946089

    We will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good....
  2. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.

    FASEB J 23(2):442-50 (2009) PMID 18842964

    We present a novel strategy toward this goal using muscarinic acetylcholine receptors as a model. The five subtypes bind their physiological transmitter in the highly conserved orthosteric site within the transmembrane domains of the receptors. Orthosteric muscarinic activators have no binding selec...
  3. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moder...

    Am J Respir Med 2(3):275-81 (2003) PMID 14720008

    Significantly greater increases in morning PEF, the primary efficacy variable, were observed in patients treated with budesonide/formoterol compared with fluticasone propionate (27.4 L/min vs 7.7 L/min; p < 0.001). Evening PEF and clinic FEV(1) also favored budesonide/formoterol compared with flutic...